帕比司他治疗儿童弥漫性内生型脑桥胶质瘤的Ⅰ期试验:儿童脑肿瘤联盟报告(PBTC-047)
该Ⅰ期试验评估口服泛组蛋白去乙酰化酶抑制剂帕比司他在儿童弥漫性内生型脑桥胶质瘤(DIPG)中的安全性、最大耐受剂量(MTD)和药代动力学。进展期DIPG(第1层)MTD为10 mg/m2/次,非进展期DIPG/弥漫性中线胶质瘤(第2层)调整方案后MTD为22 mg/m2/次;两方案最常见毒性均为骨髓抑制。
要点
- 进展期DIPG第1层:帕比司他每周3次、用3周停1周,MTD为10 mg/m2/次。
- 非进展期DIPG/DMG第2层:改用每周3次、隔周用药,MTD升至22 mg/m2/次。
- 两方案最常见毒性均为骨髓抑制,剂量限制毒性包括血小板减少和中性粒细胞减少。
核心结论
- 进展期DIPG/DMG儿童中,帕比司他每周3次、用3周停1周的MTD为10 mg/m2/次。
- 非进展期相似人群中,帕比司他每周3次、用1周停1周的MTD为22 mg/m2/次。
- 两种方案最常见毒性均为骨髓抑制。
研究设计与样本
- Ⅰ期试验,儿童脑肿瘤联盟PBTC-047,分两层评估帕比司他治疗儿童DIPG。
- 第1层纳入进展期DIPG,帕比司他每周3次、用3周停1周,剂量递增采用两阶段持续 reassessment 方法。
- 第1层MTD确定后方案修订,第2层纳入非进展期DIPG/DMG,改用每周3次、隔周用药以尝试提高剂量。
- 第1层19例入组,17/19可评估剂量探索;第2层34例合格入组,29/34可评估剂量探索。
主要发现
- 第1层MTD为10 mg/m2/次,剂量限制毒性包括血小板减少和中性粒细胞减少,1例报告可逆性后部脑病综合征。
- 第2层MTD为22 mg/m2/次,剂量限制毒性包括血小板减少、中性粒细胞减少、中性粒细胞减少伴4级血小板减少、持续性不耐受恶心和ALT升高。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Diffuse intrinsic pontine glioma (DIPG) is a lethal childhood cancer with median survival of less than 1 year. Panobinostat is an oral multihistone deacetylase inhibitor with preclinical activity in DIPG models. Study objectives were to determine safety, tolerability, maximum tolerated dose (MTD), toxicity profile, and pharmacokinetics of panobinostat in children with DIPG. PATIENTS AND METHODS: In stratum 1, panobinostat was administered 3 days per week for 3 weeks on, 1 week off to children with progressive DIPG, with dose escalation following a two-stage continual reassessment method. After this MTD was determined, the study was amended to evaluate the MTD in children with nonprogressive DIPG/Diffuse midline glioma (DMG) (stratum 2) on an alternate schedule, 3 days a week every other week in an effort to escalate the dose. RESULTS: For stratum 1, 19 subjects enrolled with 17/19 evaluable for dose-finding. The MTD was 10 mg/m2/dose. Dose-limiting toxicities included thrombocytopenia and neutropenia. Posterior reversible encephalopathy syndrome was reported in 1 patient. For stratum 2, 34 eligible subjects enrolled with 29/34 evaluable for dose finding. The MTD on this schedule was 22 mg/m2/dose. DLTs included thrombocytopenia, neutropenia, neutropenia with grade 4 thrombocytopenia, prolonged intolerable nausea, and increased ALT. CONCLUSIONS: The MTD of panobinostat is 10 mg/m2/dose administered 3 times per week for 3 weeks on/1 week off in children with progressive DIPG/DMG and 22 mg/m2/dose administered 3 times per week for 1 week on/1 week off when administered in a similar population preprogression. The most common toxicity for both schedules was myelosuppression.
引用
- Monje M, Cooney T, Glod J, et al. Phase I trial of panobinostat in children with diffuse intrinsic pontine glioma: A report from the Pediatric Brain Tumor Consortium (PBTC-047). Neuro Oncol. 2023. PMID: 37526549. doi:10.1093/neuonc/noad141
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。